Literature DB >> 30359135

Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution.

Céline Anquetil1,2, Joe-Elie Salem3,4, Bénédicte Lebrun-Vignes3, Douglas B Johnson5, Andrew L Mammen6,7, Werner Stenzel4,8, Sarah Léonard-Louis9, Olivier Benveniste1,2, Javid J Moslehi4,5, Yves Allenbach1,2.   

Abstract

Entities:  

Keywords:  antineoplastic agent, immunological; autoimmune diseases; myasthenia gravis; myocarditis; myositis

Mesh：

Substances：

Year:  2018        PMID： 30359135     DOI： 10.1161/CIRCULATIONAHA.118.035898

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  34 in total

Review 1.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

2.  Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?

Authors:  Mitchell S von Itzstein; Shaheen Khan; Vinita Popat; Rong Lu; Saad A Khan; Farjana J Fattah; Jason Y Park; Bonnie L Bermas; David R Karp; Murtaza Ahmed; Jessica M Saltarski; Yvonne Gloria-McCutchen; Yang Xie; Quan-Zhen Li; Edward K Wakeland; David E Gerber
Journal:  Oncologist       Date:  2020-06-03

3.  Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer.

Authors:  Amy Cunningham-Bussel; Jiaqi Wang; Lauren C Prisco; Lily W Martin; Kathleen M M Vanni; Alessandra Zaccardelli; Mazen Nasrallah; Lydia Gedmintas; Lindsey A MacFarlane; Nancy A Shadick; Mark M Awad; Osama Rahma; Nicole R LeBoeuf; Ellen M Gravallese; Jeffrey A Sparks
Journal:  Arthritis Rheumatol       Date:  2022-01-25       Impact factor: 10.995

Review 4.  Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies.

Authors:  Morinobu Seki; Shigehisa Kitano; Shigeaki Suzuki
Journal:  Cancer Immunol Immunother       Date:  2021-09-13       Impact factor: 6.968

Review 5.  Cardiotoxicity of Systemic Melanoma Treatments.

Authors:  Neha Mukunda; Srilakshmi Vallabhaneni; Benedicte Lefebvre; Michael G Fradley
Journal:  Curr Treat Options Oncol       Date:  2022-02-22

6.  Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.

Authors:  Virginie Grouthier; Bénédicte Lebrun-Vignes; Melissa Moey; Douglas B Johnson; Javid J Moslehi; Joe-Elie Salem; Anne Bachelot
Journal:  Oncologist       Date:  2020-05-17

7.  Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Authors:  G Curigliano; D Lenihan; M Fradley; S Ganatra; A Barac; A Blaes; J Herrmann; C Porter; A R Lyon; P Lancellotti; A Patel; J DeCara; J Mitchell; E Harrison; J Moslehi; R Witteles; M G Calabro; R Orecchia; E de Azambuja; J L Zamorano; R Krone; Z Iakobishvili; J Carver; S Armenian; B Ky; D Cardinale; C M Cipolla; S Dent; K Jordan
Journal:  Ann Oncol       Date:  2020-02       Impact factor: 32.976

Review 8.  Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.

Authors:  Javid Moslehi; Andrew H Lichtman; Arlene H Sharpe; Lorenzo Galluzzi; Richard N Kitsis
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 9.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124

Review 10.  Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment.

Authors:  Xiaohu Zheng; Haiming Wei
Journal:  Front Oncol       Date:  2021-05-21       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.